Dataset opportunity
Bridgetolife — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Bridgetolife, usable for Diagnostic AI and Computer Vision.
Score
70.8
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Medical Diagnostics Market was valued at $1.1 Billion in 2023, with a projected CAGR of 25.2% (2024-2033).
Recent dated external facts that triggered this opportunity — auditable provenance.
- 📰press2026-08-12
Bridge to Life raises $110m to advance liver perfusion system’s rollout
medicaldevice-network.com ↗
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Real-time
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Bridgetolife provides a high-value Medical Imaging Dataset from clinical trials, which includes image modalities, proprietary machine perfusion telemetry (`iot_data`), and associated `medical_records`. This multi-modal dataset is uniquely structured for training and validating Diagnostic AI algorithms, as it is directly linked to `regulatory` submissions with the FDA.
This data is positioned within the global AI in Medical Diagnostics market, estimated at $1.1 Billion in 2023 and projected to grow at a CAGR of 25.2%. [4] While access requires navigating complexities such as its status as highly sensitive clinical trial data (HIPAA/GDPR) and its connection to FDA regulatory submissions, its rarity and direct relevance make it a crucial asset for entities aiming to lead in the rapidly expanding diagnostic AI field. ⚠ Diligence (valuable data, access to negotiate): Highly sensitive clinical trial data (HIPAA/GDPR); Data tied to FDA regulatory submissions; Proprietary machine perfusion telemetry requires specific extraction · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence proves Bridgetolife holds proprietary data from a pivotal multicenter clinical trial focused on hypothermic oxygenated perfusion (HOPE) for organ grafts. This rare dataset, combining medical imaging, IoT device outputs, and regulatory research, is ideal for diagnostic AI companies seeking to develop models that predict organ viability. In a rapidly growing AI diagnostics market, valued at over $1.1 billion in 2023, this trial-grade data provides a unique foundation for creating tools that guide critical graft utilization decisions.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness82
real-time/streaming
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand95
Buyer demand is exceptionally high, driven by the explosive 25.2% CAGR of the AI in Medical Diagnostics market, which creates intense competition for high-quality, regulatory-grade training data. [4]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
high difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=company_owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 data-appetite signals (2 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high, 1 recent external signals — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ good target — The company's core business is selling medical devices for organ preservation, and the valuable clinical data generated from R&D and trials appears to be a dormant by-product, making it a strong target. Issues: The initial sourcing description 'Medical Imaging Dataset Opportunity' is incorrect; the company's business is organ preservation technology and solutions, not
- Deep Qualification80
✓ pass — The target is a tooling vendor selling organ preservation hardware; the data is a byproduct of their FDA-mandated clinical trials. Data ownership is mixed, involving the company, hospitals, and patients, and is highly sensitive (HIPAA/GDPR), making access complex despite its high value.
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
This evidence points to a collection of medical images generated during a pivotal clinical trial, which is highly sought after by diagnostic AI developers for training models to assess organ health.
IoT / sensor data
This sample indicates the availability of time-series data from the VitaSmart™ perfusion system, which is essential for developing multimodal AI that predicts transplant success based on real-time organ metrics.
Regulatory records
This text-based evidence comprises research focused on identifying biomarkers for graft utilization, providing the scientific and regulatory context needed to validate a diagnostic AI's clinical utility.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Coverage
Scanned sources
Deliverable
Premium dataset report
Bridgetolife Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Diagnostics Market was valued at $1.1 Billion in 2023, with a projected CAGR of 25.2% (2024-2033) (source: Market.us). [4]. Investment score 70.8/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Intelligent Implants — Medical Imaging Dataset Opportunity
View opportunity →healthcareYourway — Sensor Telemetry Dataset Opportunity
View opportunity →healthcareMazzetti — Public Procurement Dataset Opportunity
View opportunity →